An Unusual Presentation of Clostridioides Difficile Colitis in a Patient on Opioids

Oluwafemi A. Ajibola 1, Taiwo O. Aremu 2, 3, Sikder Hassan 1, Nili Gujadhur 1, Valerie Cluzet 1

1. Department of Medicine, Nuvance Health, Vassar Brothers Medical Center, Poughkeepsie, USA 2. Department of Pharmaceutical Care & Health Systems, College of Pharmacy, University of Minnesota, Minneapolis, USA 3. Division of Environmental Health Sciences, School of Public Health, University of Minnesota, Minneapolis, USA

Corresponding author: Oluwafemi A. Ajibola, oluwafemi.ajibola@nuvancehealth.org

Abstract
Clostridioides difficile colitis is an inflammation of the colon due to toxins produced by a gram-positive bacterium called Clostridioides difficile (also known as Clostridium difficile). Clostridioides difficile colitis is associated with an increased risk of morbidity and mortality in elderly patients. The infection develops because of the disruption of the microbiome that usually suppresses the overgrowth of Clostridioides difficile. Testing for Clostridium difficile infection is routinely recommended in patients with at least three loose bowel movements in a day. We present an unusual case of a 74-year-old woman on chronic opioids who presented with a three-day history of lower abdominal pain, constipation, hematochezia, with no diarrhea. Radiologic imaging showed evidence of colitis, and the patient was found to have Clostridium difficile colitis.

Categories: Internal Medicine, Gastroenterology, Infectious Disease
Keywords: clostridioides difficile colitis, hematochezia, constipation, diarrhea, antibiotics, opioids, colitis, clostridium difficile

Introduction
Clostridioides difficile colitis is caused by toxins produced by Clostridioides difficile (also known as Clostridium difficile or C. difficile), a gram-positive, spore-forming, obligate anaerobic rod bacterium [1]. According to the Centers for Disease Control and Prevention (CDC), C. difficile causes almost 500,000 infections in the United States each year [2]. The infection is typically related to antibiotic use, usually misuse and overuse, which often characterize antimicrobial resistance [3]. The current recommendations by the American College of Gastroenterology, the Infectious Diseases Society of America, and our local health institution support testing for C. difficile only in patients having diarrhea (defined as three or more loose stools within 24 hours) and after holding off laxative medications [4,5]. We present an unusual case of C. difficile colitis in a patient on opioids with no diarrhea.

Case Presentation
A 74-year-old woman presented to the emergency department with a three-day history of lower abdominal pain, constipation, and blood in the stool (hematochezia) four days after a recent hospitalization for community-acquired pneumonia. She has a past medical history of anxiety, depression, chronic obstructive pulmonary disease, hypertension, hyperlipidemia, coronary artery disease, gastroesophageal reflux disease, mild-moderate mitral regurgitation, hypothyroidism, systemic lupus erythematosus, substance use disorder on methadone maintenance, and constipation. Before her recent discharge from the hospital, she was treated with ceftriaxone and azithromycin.

On admission, she had a low-grade temperature of 99.4°F, blood pressure of 137/73 mmHg, respiratory rate of 20/minute, heart rate of 70 beats per minute, and oxygen saturation of 100% on room air. Physical examination was remarkable for dry mucous membranes and abdominal tenderness in the left upper and lower quadrants. Rectal examination showed a normal tone with frank blood. Laboratory studies revealed leukocytosis with absolute neutrophilia, normal hemoglobin level, thrombocytosis, elevated blood urea nitrogen and creatinine, hyponatremia, hypokalemia, and normal serum lactic acid levels (Table 1).
| Laboratory parameter       | Patient’s value | Reference range      |
|---------------------------|-----------------|----------------------|
| White blood cell count    | 17.9 k/µL       | 3.5–10 k/µL          |
| Neutrophils               | 83%             | 40–75%               |
| Hemoglobin                | 11.5 g/dL       | 12–16 g/dL           |
| Platelet count            | 197 k/mm$^3$    | 150–400 k/mm$^3$     |
| Blood urea nitrogen       | 25.8 mg/dL      | 6–20 mg/dL           |
| Creatinine                | 1.86 mg/dL      | 0.4–1mg/dL           |
| Sodium                    | 131 mmol/L      | 136–145 mmol/L       |
| Potassium                 | 5.5 mmol/L      | 3.5–5.1 mmol/L       |
| Lactic acid               | 1 mmol/L        | ≤2.0 mmol/L          |

**TABLE 1: Laboratory values**

A non-contrast computed tomography (CT) scan of the abdomen and pelvis showed a moderate amount of stool throughout the colon, suggesting constipation and mural thickening in the rectum and proximal sigmoid colon concerning for colitis (Figure 1).

**FIGURE 1:** CT of the abdomen and pelvis without contrast showing a moderate amount of stool throughout the colon, and mural thickening in the rectum and proximal sigmoid colon.

The green arrows indicate areas of moderate amount of stool in the colon. The red arrow indicates an area of mural thickening.
While in the emergency department, the patient had a single loose stool with brown and bloody components. She was started on intravenous fluids and broad-spectrum antibiotics, namely ceftriaxone and metronidazole. Due to recent antibiotic exposure and evidence of colitis on the CT scan, the patient was tested for *C. difficile*. Both *C. difficile* DNA PCR and toxin were positive. The patient was then placed on contact precautions, parenteral antibiotics were discontinued, and she was started on oral vancomycin. On day 5 of hospitalization, an abdominal X-ray was performed to evaluate abdominal distension, which showed no evidence of free intraperitoneal air, dilated colon, or obstruction (Figure 2).

FIGURE 2: Abdominal X-ray showing no evidence of free intraperitoneal air, dilated colon, or obstruction.

She was treated for methadone-induced constipation with methylaltrexone bromide. Subsequently, her abdominal pain, leukocytosis, and renal failure improved, and hematochezia resolved. The patient was discharged home on day 8 in stable condition.

**Discussion**

*Clostridioides difficile* has a wide range of clinical manifestations, from asymptomatic colonization to fulminant disease with toxic megacolon. *Clostridioides difficile* infection is associated with an increased risk of morbidity and mortality in the elderly (aged 65 years and older) [2]. Besides, around 9% of the elderly who have been diagnosed with healthcare-associated *C. difficile* infection die within one month [2]. In addition to pneumonia and surgical site infections, *C. difficile* infection is a leading cause of nosocomial infection in the United States [6-8]. In 2017, hospitalized patients accounted for around 223,900 cases of nosocomial *C. difficile* and around 12,800 deaths in the United States [9].

The normal microbiota of healthy intestines often suppresses the growth of *C. difficile*, and disruption of the microbiome can lead to the overgrowth of the bacteria [10,11]. The *C. difficile* bacterium produces toxins A and B that disrupt the cytoskeleton of the colon, hence leading to pseudomembranous colitis [11]. Risk factors for *C. difficile* infection include exposure to antibiotics, age 65 years and older, recent hospitalization or nursing home stay, immunosuppression (including HIV/AIDS, cancer, and organ transplantation), immunosuppressive therapies, hypoalbuminemia, and previous *C. difficile* infection [2,11]. Symptoms include diarrhea (defined as at least three loose bowel movements in a day), fever, abdominal pain, nausea, and loss of appetite.

The American College of Gastroenterology, the Infectious Diseases Society of America, and our institutional
guidelines recommend only testing for *C. difficile* in patients with diarrhea [4,5]. In our case, the patient did not present with diarrhea and did not meet the criteria for testing based on the current guidelines. It is important to note that the patient was on methadone maintenance, a long-acting opioid with constipation as one of its major side effects. In addition, elderly individuals are also at an increased risk of constipation due to decreased gastrointestinal motility. The side effect of this medication and the patient’s age likely masked the usual symptoms of *C. difficile* colitis, specifically diarrhea. Although the patient did not meet the criteria for testing based on stool frequency, she warranted testing given other consistent symptoms, recent antibiotic exposure, markedly elevated white blood cell count, and evidence of colitis on the abdominal CT scan.

**Conclusions**

*Clostridioides difficile* infection is associated with significant morbidity and mortality in individuals aged 65 years and older. The early diagnosis of *C. difficile* colitis can decrease the risk of transmission, length of hospital stays, and mortality. Although the current recommendations do not support testing patients who present without diarrhea, suspicion for *C. difficile* infection should still be maintained in patients on anti-motility agents who have other clinical signs and symptoms consistent with *C. difficile* colitis.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Burke KE, Lamont JT: Clostridium difficile infection: a worldwide disease. Gut Liver. 2014, 8:1-6. 10.5009/gnl.2014.8.1.1
2. Centers for Disease Control and Prevention. Could you or your loved one have C. diff? (2021). Accessed: March 29, 2022: https://www.cdc.gov/cdiff/what-is.html.
3. Aremu TO, Oluwole OE, Adeyinka KO: An understanding of the drivers of infectious diseases in the modern world can aid early control of future pandemics. Pharmacy (Basel). 2021, 9:181. 10.3390/pharmacy9040181
4. Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, Stallman NH: ACG clinical guidelines: prevention, diagnosis, and treatment of *Clostridioides difficile* Infections. Am J Gastroenterol. 2021, 116:1124-47. 10.14309/aig.0000000000001278
5. McDonald LC, Gerding DN, Johnson S, et al.: Clinical practice guidelines for *Clostridioides difficile* infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018, 66:e1-e48. 10.1093/cid/cix1085
6. Magill SS, O’Leary E, Janelle SJ, et al.: Changes in prevalence of health care-associated infections in U.S. hospitals. N Engl J Med. 2018, 379:1732-44. 10.1056/NEJMoa1801550
7. McGee RB: Nosocomial or hospital-acquired infections: an overview. Dis Mon. 2009, 55:422-58. 10.1016/j.dismon.2009.05.014
8. Abbas A, Zachular JP: Microbe-microbe interactions during *Clostridioides difficile* infection. Curr Opin Microbiol. 2020, 53:19-23. 10.1016/j.mib.2020.01.016
9. Centers for Disease Control and Prevention. Healthcare-Associated Infections (HAIs): *Clostridioides difficile* Infection. (2020). Accessed: April 2, 2022: https://www.cdc.gov/hai/organisms/cdiff/cdiff_infect.html.
10. Burns DA, Heap JT, Minton NP: *Clostridium difficile* spore germination: an update. Res Microbiol. 2010, 161:730-4. 10.1016/j.resmic.2010.09.007
11. Di Bella S, Ascenzi F, Sirakas S, Petroillo N, di Maio A: *Clostridium difficile* toxins A and B: insights into pathogenic properties and extraintestinal effects. Toxins (Basel). 2016, 8:154. 10.3390/toxins8050154